Source comparison
BPC-157 Research Perimenopause Considerations: Protocol Comparison
Subject Selection No hormonal screening Baseline estradiol, progesterone, FSH profiling required Reduces inter-subject variance by 25–30% Dosing Schedule Fixed calendar-based timing Cycle-synchronized or covariate-adjusted Improves dose-response clarity by 20–
This comparison does not assign a generated winner or score.
- Subject Selection
- No hormonal screening
- Baseline estradiol, progesterone, FSH profiling required
- Reduces inter-subject variance by 25–30%
- Dosing Schedule
- Fixed calendar-based timing
- Cycle-synchronized or covariate-adjusted
- Improves dose-response clarity by 20–25%
- Inflammatory Profiling
- Not routinely measured
- Baseline IL-6, CRP, TNF-alpha stratification
- Identifies biologically distinct subgroups, tightens CI by 20%
- Endpoint Measurement Windows
- Fixed (e.g., 7, 14, 28 days post-dose)
- Extended or cycle-phase aligned (luteal vs follicular)
- Captures peak effect timing more accurately
- Baseline VEGF Measurement
- Rarely included
- Mandatory for angiogenic studies
- Explains 30–40% of outcome variance otherwise attributed to noise